The over-arching objectives of this project are to develop and apply biomarker assays for evaluating human reproductive health at the population level. Risk to reproductive health is an area of growing public concern. Initially, this project focuses on the development of biomarker assays that can be applied to non-clinical situations and permit epidemiological studies to include prospective evaluations of individual women's reproductive health. The same biomarker assays validated for use in humans are also validated for use in the nonhuman primate animal model because the species-specific aspects of human reproduction often require the use of the laboratory macaque. These assays are then used to conduct in vivo experiments using the non-human primate animal model to fill important gaps in our understanding of specific environmental toxicants including targets of toxicity and exposure risks. The development of biomarkers for effect has subsequently led to the development and validation of biomarker assays for exposure to reproductive health risks and the identification of new environmental toxicants. All assays are adapted to automated platforms so that they are immediately available for use in all research and clinical centers, in vivo experiments conducted to confirm and characterize newly identified reproductive hazards and in vitro experiments using human cells lines are used to develop a deeper understanding of their mechanism(s) of action. Whenever possible, archival biological samples from previous or concurrent epidemiological studies are used in order to pose population-based queries that otherwise could not be addressed within the budget of a single project. Cooperation and collaboration with other projects is emphasized.

Public Health Relevance

This project addresses the real and potential deleterious effects of environmental hazards on human reproductive health, concentrating on environmental risks to human reproduction and development at the population-based level.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-27
Application #
8450323
Study Section
Special Emphasis Panel (ZES1-LWJ-M)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
27
Fiscal Year
2013
Total Cost
$146,169
Indirect Cost
$52,361
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications